drugset / Trial / NCT01159496

Multiple Ascending Dose Study To Assess Safety, Tolerability And Pharmacokinetics Of PF-05212377 (SAM-760)

NCT01159496

Phase 1 Completed 60 enrolled Pfizer
RandomizedSingle-groupDouble-blind

Summary

This is a multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of PF-05212377 (SAM-760) administered orally once a day for 14 days to healthy young adults and healthy elderly subjects. The study will be conducted under double-blind conditions (neither the investigator nor the subject will know if he/she has received PF-05212377 or a placebo). The Sponsor will know if the subject has received active treatment or a placebo.

Timeline

Start
2010-07
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-05212377 Small molecule 1.5 mg Oral
Subject PF-05212377 Small molecule 5 mg Oral
Subject PF-05212377 Small molecule 15 mg Oral
Subject PF-05212377 Small molecule 30 mg Oral
Subject PF-05212377 Small molecule 50 mg Oral

Indications

No indication recorded.